Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
Frontiers in Oncology
|
December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)
|
December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)
|
February 26, 2025
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting <i>Salmonella typhimurium</i> A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice
Sei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis
|
January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
August 28, 2024
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
January 31, 2025
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Cancer Genomics & Proteomics
|
October 28, 2024
Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cells which Report DNA-Damage Response in Real Time
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
August 28, 2024
Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
Frontiers in Oncology
|
December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)
|
December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)
|
February 26, 2025
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting <i>Salmonella typhimurium</i> A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice
Sei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis
|
January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
August 28, 2024
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
January 31, 2025
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Cancer Genomics & Proteomics
|
October 28, 2024
Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cells which Report DNA-Damage Response in Real Time
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
August 28, 2024
Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Page
of 8